| 1. |
Suchánková G, Spicák J. Sorafenib in the treatment of hepatocellular carcinoma[J]. Vnitr Lek, 2011, 57(5): 485-490.
|
| 2. |
Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2003, 362(9399): 1907-1917.
|
| 3. |
Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress[J]. J Clin Oncol, 2005(23): 2892-2899.
|
| 4. |
Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J]. Cancer Res, 2006, 66(24): 11851-11858.
|
| 5. |
Huynh H, Ngo VC, Koong HN, et al. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma[J]. J Cell Mol Med, 2009, 13(8B): 2673-2683.
|
| 6. |
Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390.
|
| 7. |
Moore M, Hirte HW, Siu L, et al. PhaseⅠ study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors[J]. Ann Oncol, 2005, 16(10): 1688-1694.
|
| 8. |
Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase Ⅱ study of sorafenib in patients with advanced hepatocellular carcinoma[J]. J Clin Oncol, 2006, 24(26): 4293-4300.
|
| 9. |
Yau T, Chan P, Ng KK, et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response[J]. Cancer, 2009, 115(2): 428-436.
|
| 10. |
Jordi B, Jean-Luc R, Morris S, et al. Effcacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subset analyses of a phase Ⅲ trial[J]. J Hepatol, 2012, 57(4): 821-829.
|
| 11. |
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34.
|
| 12. |
Cheng AL, Guan Z, Chen Z, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phaseⅢ Sorafenib Asia-Pacific trial[J]. Eur J Cancer, 2012, 48(10): 1452-1465.
|
| 13. |
Abou-Alfa GK, Amadori D, Santoro A, et al. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma(HCC) and Child-Pugh B (CPB) cirrhosis?[J]. Clin Oncol, 2008, 26(15S): 4518.
|
| 14. |
Pinter M, Sieghart W, Graziadei I, et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis[J]. Oncologist, 2009, 14(1): 70-76.
|
| 15. |
Abou-Alfa GK, Amadori D, Santoro A, et al. Safety and ef?cacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis[J]. Gastrointest Cancer, Res 2011, 4(2): 40-44.
|
| 16. |
Hollebecque A, Cattan S, Romano O, et al. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score[J]. Aliment Pharmacol Ther, 2011, 34(10): 1193-1201.
|
| 17. |
Wong H, Tang YF, Yao TJ, et al. The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC)[J]. Oncologist, 2011, 16(12): 1721-1728.
|
| 18. |
Lencioni R, Marrero J, Venook A, et al. Design and rationale for the non-interventional Global Investigation of therapeutic Decisions in hepatocellular carcinoma and of its treatment with sorafeNib (GIDEON) study[J]. Int J Clin Pract, 2010, 64(8): 1034-1041.
|
| 19. |
Abou-Alfa GK, Johnson P, Knox J, et al. Final results from a phaseⅡ(PhⅡ), randomized, double-blind study of sorafenib plus doxorubicin(S+D) versus placebo plus doxorubicin(P+D) in patients(pts) with advanced hepatocellular carcinoma (AHCC)[R]. Orlando (FL), 2008.
|
| 20. |
Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial[J]. JAMA, 2010, 304(19): 2154-2160.
|
| 21. |
Petrini I, Lencioni M, Ricasoli M, et al. Phase Ⅱ trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma[J]. Cancer Chemother Pharmacol, 2011, 69(3): 773-780.
|
| 22. |
Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma[J]. Korean J Radiol, 2009, 10(5): 425-434.
|
| 23. |
Cabrera R, Pannu DS, Caridi J, et al. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2011, 34(2): 205-213.
|
| 24. |
Kudo M, Imanaka K, Chida N, et al. Phase Ⅲ study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma[J]. Eur J Cancer, 2011, 47(14): 2117-2127.
|
| 25. |
Pawlik TM, Reyes DK, Cosgrove D, et al. Phase Ⅱ trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma[J]. J Clin Oncol, 2011, 29(30): 3960-3967.
|
| 26. |
Sieghart W, Pinter M, Reisegger M, et al. Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study[J]. Eur Radiol, 2012, 22(6): 1214-1223.
|
| 27. |
Hoffmann K, Glimm H, Radeleff B, et al. Prospective, randomized, double-blind, multi-center, PhaseⅢ clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation-HeiLivCa[ISRCTN24081794][J]. BMC Cancer, 2008, 8: 349.
|
| 28. |
Spangenberg HC, Thimme R, Blum H. Evolving therapies in the treatment of hepatocellular carcinoma[J]. Biologics, 2008, 2(3): 453-462.
|
1/5
微信公眾號